ArticleDermatology and therapy2026
Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04392154 (A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe report efficacy and safety of lebrikizumab up to 152 weeks (W) of continuous treatment with/without topical corticosteroids in the ADjoin long-term extension study.
methodsADvocate1&2 W16 lebrikizumab responders (Eczema Area and Severity Index (EASI) 75 or Investigator's Global Assessment (IGA) 0/1 without rescue) were re-randomized 2:2:1 lebrikizumab (LEB) 250 mg Q2W, Q4W, or placebo (lebrikizumab withdrawal, not presented herein) to the 36W maintenance period before entering ADjoin. ADhere W16 lebrikizumab responders were re-randomized 2:1 LEBQ2W/Q4W upon entering ADjoin. Data are reported as observed for W16 lebrikizumab responders from ADvocate1&2 (N = 181) and ADhere (N = 86) who received treatment up to ADjoin W100 (152W/116W for ADvocate1&2/ADhere). The Supplement reports additional populations.
resultsIn participants who achieved IGA 0/1 at W16, 84.0% (Q4W) and 82.9% (Q2W) from ADvocate1&2 maintained IGA 0/1 at W152; 91.7% and 86.7% from ADhere maintained response at W116. Among participants achieving EASI 75 at W16, 94.1% (Q4W) and 90.5% (Q2W) from ADvocate1&2 maintained EASI 75 at W152; 90.9% and 94.9% from ADhere maintained EASI 75 at W116. Most adverse events (AEs) were mild (29.2%) or moderate (33.3%) in severity; 3.7% reported serious AEs; 2.6% reported AEs leading to treatment discontinuation.
conclusionLebrikizumab maintained efficacy up to 3 years of continuous treatment in LEB 250 mg Q2W and Q4W W16 lebrikizumab per-protocol responders. The safety profile was consistent with previous studies.
trial registrationClinicalTrials.gov identifier, NCT04392154.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.